Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes

Loïc Martin, François Stricher, Dorothée Missé, Francesca Sironi, Martine Pugnière, Philippe Barthe, Rafael Prado-Gotor, Isabelle Freulon, Xavier Magne, Christian Roumestand, André Ménez, Paolo Lusso, Francisco Veas, Claudio Vita

Research output: Contribution to journalArticle

Abstract

The conserved surfaces of the human immunodeficiency virus (HIV)-1 envelope involved in receptor binding represent potential targets for the development of entry inhibitors and neutralizing antibodies. Using structural information on a CD4-gp120-17b antibody complex, we have designed a 27-amino acid CD4 mimic, CD4M33, that presents optimal interactions with gp120 and binds to viral particles and diverse HIV-1 envelopes with CD4-like affinity. This mini-CD4 inhibits infection of both immortalized and primary cells by HIV-1, including primary patient isolates that are generally resistant to inhibition by soluble CD4. Furthermore, CD4M33 possesses functional properties of CD4, including the ability to unmask conserved neutralization epitopes of gp120 that are cryptic on the unbound glycoprotein. CD4M33 is a prototype of inhibitors of HIV-1 entry and, in complex with envelope proteins, a potential component of vaccine formulations, or a molecular target in phage display technology to develop broad-spectrum nuetralizing antibodies.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalNature Biotechnology
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 1 2003

Fingerprint

Epitopes
Virus Internalization
Viruses
HIV-1
Antibodies
Glycoproteins
Bacteriophages
Vaccines
Neutralizing Antibodies
Virion
Amino acids
Display devices
Technology
Proteins
Amino Acids
Infection

ASJC Scopus subject areas

  • Microbiology

Cite this

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. / Martin, Loïc; Stricher, François; Missé, Dorothée; Sironi, Francesca; Pugnière, Martine; Barthe, Philippe; Prado-Gotor, Rafael; Freulon, Isabelle; Magne, Xavier; Roumestand, Christian; Ménez, André; Lusso, Paolo; Veas, Francisco; Vita, Claudio.

In: Nature Biotechnology, Vol. 21, No. 1, 01.01.2003, p. 71-76.

Research output: Contribution to journalArticle

Martin, L, Stricher, F, Missé, D, Sironi, F, Pugnière, M, Barthe, P, Prado-Gotor, R, Freulon, I, Magne, X, Roumestand, C, Ménez, A, Lusso, P, Veas, F & Vita, C 2003, 'Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes', Nature Biotechnology, vol. 21, no. 1, pp. 71-76. https://doi.org/10.1038/nbt768
Martin, Loïc ; Stricher, François ; Missé, Dorothée ; Sironi, Francesca ; Pugnière, Martine ; Barthe, Philippe ; Prado-Gotor, Rafael ; Freulon, Isabelle ; Magne, Xavier ; Roumestand, Christian ; Ménez, André ; Lusso, Paolo ; Veas, Francisco ; Vita, Claudio. / Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. In: Nature Biotechnology. 2003 ; Vol. 21, No. 1. pp. 71-76.
@article{6171e8a05bdd40d68382cf250d82fe6d,
title = "Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes",
abstract = "The conserved surfaces of the human immunodeficiency virus (HIV)-1 envelope involved in receptor binding represent potential targets for the development of entry inhibitors and neutralizing antibodies. Using structural information on a CD4-gp120-17b antibody complex, we have designed a 27-amino acid CD4 mimic, CD4M33, that presents optimal interactions with gp120 and binds to viral particles and diverse HIV-1 envelopes with CD4-like affinity. This mini-CD4 inhibits infection of both immortalized and primary cells by HIV-1, including primary patient isolates that are generally resistant to inhibition by soluble CD4. Furthermore, CD4M33 possesses functional properties of CD4, including the ability to unmask conserved neutralization epitopes of gp120 that are cryptic on the unbound glycoprotein. CD4M33 is a prototype of inhibitors of HIV-1 entry and, in complex with envelope proteins, a potential component of vaccine formulations, or a molecular target in phage display technology to develop broad-spectrum nuetralizing antibodies.",
author = "Lo{\"i}c Martin and Fran{\cc}ois Stricher and Doroth{\'e}e Miss{\'e} and Francesca Sironi and Martine Pugni{\`e}re and Philippe Barthe and Rafael Prado-Gotor and Isabelle Freulon and Xavier Magne and Christian Roumestand and Andr{\'e} M{\'e}nez and Paolo Lusso and Francisco Veas and Claudio Vita",
year = "2003",
month = "1",
day = "1",
doi = "10.1038/nbt768",
language = "English",
volume = "21",
pages = "71--76",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes

AU - Martin, Loïc

AU - Stricher, François

AU - Missé, Dorothée

AU - Sironi, Francesca

AU - Pugnière, Martine

AU - Barthe, Philippe

AU - Prado-Gotor, Rafael

AU - Freulon, Isabelle

AU - Magne, Xavier

AU - Roumestand, Christian

AU - Ménez, André

AU - Lusso, Paolo

AU - Veas, Francisco

AU - Vita, Claudio

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The conserved surfaces of the human immunodeficiency virus (HIV)-1 envelope involved in receptor binding represent potential targets for the development of entry inhibitors and neutralizing antibodies. Using structural information on a CD4-gp120-17b antibody complex, we have designed a 27-amino acid CD4 mimic, CD4M33, that presents optimal interactions with gp120 and binds to viral particles and diverse HIV-1 envelopes with CD4-like affinity. This mini-CD4 inhibits infection of both immortalized and primary cells by HIV-1, including primary patient isolates that are generally resistant to inhibition by soluble CD4. Furthermore, CD4M33 possesses functional properties of CD4, including the ability to unmask conserved neutralization epitopes of gp120 that are cryptic on the unbound glycoprotein. CD4M33 is a prototype of inhibitors of HIV-1 entry and, in complex with envelope proteins, a potential component of vaccine formulations, or a molecular target in phage display technology to develop broad-spectrum nuetralizing antibodies.

AB - The conserved surfaces of the human immunodeficiency virus (HIV)-1 envelope involved in receptor binding represent potential targets for the development of entry inhibitors and neutralizing antibodies. Using structural information on a CD4-gp120-17b antibody complex, we have designed a 27-amino acid CD4 mimic, CD4M33, that presents optimal interactions with gp120 and binds to viral particles and diverse HIV-1 envelopes with CD4-like affinity. This mini-CD4 inhibits infection of both immortalized and primary cells by HIV-1, including primary patient isolates that are generally resistant to inhibition by soluble CD4. Furthermore, CD4M33 possesses functional properties of CD4, including the ability to unmask conserved neutralization epitopes of gp120 that are cryptic on the unbound glycoprotein. CD4M33 is a prototype of inhibitors of HIV-1 entry and, in complex with envelope proteins, a potential component of vaccine formulations, or a molecular target in phage display technology to develop broad-spectrum nuetralizing antibodies.

UR - http://www.scopus.com/inward/record.url?scp=12244281787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244281787&partnerID=8YFLogxK

U2 - 10.1038/nbt768

DO - 10.1038/nbt768

M3 - Article

C2 - 12483221

AN - SCOPUS:12244281787

VL - 21

SP - 71

EP - 76

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 1

ER -